RE:why would a biotech company put on hold From the Q call transcript:
Operator
Your next question comes from Edwin Zhang of H.C. Wainwright.
Edwin Zhang
First one, can you provide us more color on your strategic business trips? What assets are under consideration for divestment from a timeline perspective, a bit more likely to happen in the second half of the year after the Ryplazim PDUFA date? And then I have a follow-up.
Bruce Pritchard
Okay. I'll maybe start off on that, and then I can ask Patrick to step in as well. But as we said in our press release, we're -- we've made the strategic decision that we'd like to focus the business on our small molecule operations going forward. So we're looking to divest our plasma business in its entirety, whether that's in 1 or multiple transactions. So we're looking to divest the plasma centers, the manufacturing operations and the Ryplazim asset. So that's the nature of what we're looking for.
I think it's without giving anything away on what we're doing with negotiations and discussions that would be commercially sensitive. The reality is that we are looking at all opportunities here, whether we do this before or after Ryplazim approval.